Engineering therapeutic bispecific antibodies using CrossMab technology.

Autor: Klein C; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, 8952 Schlieren, Switzerland. Electronic address: christian.klein.ck1@roche.com., Schaefer W; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, 82393 Penzberg, Germany., Regula JT; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, 82393 Penzberg, Germany., Dumontet C; Cancer Research Center of Lyon (CRCL), INSERM, 1052/CNRS, 69000 Lyon, France., Brinkmann U; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, 82393 Penzberg, Germany., Bacac M; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, 8952 Schlieren, Switzerland., Umaña P; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, 8952 Schlieren, Switzerland.
Jazyk: angličtina
Zdroj: Methods (San Diego, Calif.) [Methods] 2019 Feb 01; Vol. 154, pp. 21-31. Date of Electronic Publication: 2018 Nov 16.
DOI: 10.1016/j.ymeth.2018.11.008
Abstrakt: Bispecific antibodies have recently gained major interest as they allow novel mechanisms-of-action and/or therapeutic applications that cannot be achieved using conventional IgG-based antibodies. A major issue in engineering IgG-based bispecific antibodies has been to enable the correct association of heavy and light chains resulting in correct assembly of the desired bispecific antibody in sufficient yield. Various approaches have been described during recent years to tackle this challenge. We have developed the so-called CrossMab technology that enforces correct light chain association based on the domain crossover of immunoglobulin domains in the Fab region of the bispecific antibody. This versatile technology allows the generation of different bispecific antibody formats including asymmetric heterodimeric monovalent 1 + 1 bispecific antibodies and asymmetric heterodimeric bispecific antibodies with 2 + 1 valency in combination with approaches enabling Fc-hetermodimerization like knob-into-hole technology as well as the generation of tetravalent symmetric bispecific antibodies with 2 + 2 valency, also known as Tandem-Fab based IgG antibodies, using processes suitable for the large scale production of therapeutic bispecific antibodies. Notably, as of now, at least eight different bispecific antibodies using CrossMab technology entered clinical development, and additional CrossMabs are in late preclinical development. This review provides a summary of the status and progress with the engineering and generation of CrossMab technology based bispecific antibodies as well as their therapeutic application.
(Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: